Anteris Secures $320M, U.S. Enrollment Starts in PARADIGM Trial
AVR•Anteris completed a $320 million capital raise in January 2026 to fund its global PARADIGM Trial and advance the DurAVR THV System toward commercialization, with U.S. enrollment now underway. The company posted $28.7 million in cash outflows and $17.5 million in R&D expenses driven by trial execution and manufacturing scaling.
1. Capital Raise Fuels Trial Execution
Anteris completed a $320 million capital raise in January 2026 to support its global PARADIGM Trial and the commercialization of its DurAVR THV System. This funding will underpin clinical site expansion, regulatory submissions, and manufacturing scale-up.
2. Progress on PARADIGM Trial
Patient enrollment progressed in Europe and commenced in the U.S. following a recent CMS coverage determination under TAVR National Coverage Determination 20.32. The trial aims to randomize 1,000 patients across multiple countries to compare DurAVR THV with commercial TAVRs.
3. Q1 Financial Results
In the quarter ended March 31, 2026, Anteris recorded $28.7 million in cash outflows and $17.5 million in R&D expenses, primarily due to clinical and manufacturing activities. Reduced DurAVR product research costs partially offset these expenditures, reflecting a focus on trial advancement.
